Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon.
about
Pharmacogenetics of erectile dysfunction: navigating into uncharted watersY-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosumAnandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB1 and vanilloid VR1 receptorsUrogenital Autonomic Dysfunction in Diabetes.Role of neural NO synthase (nNOS) uncoupling in the dysfunctional nitrergic vasorelaxation of penile arteries from insulin-resistant obese Zucker rats.Pathophysiology of colonic causes of chronic constipationAdenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse.Erectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177Adventures in vascular biology: a tale of two mediators.Current oral treatments for erectile dysfunction.A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.Arginase II deletion increases corpora cavernosa relaxation in diabetic mice.Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunctionExercise training improves the defective centrally mediated erectile responses in rats with type I diabetesThe discovery of nitric oxide and its role in vascular biology.Erectile dysfunction - an update of current practice and future strategies.Relationship between Metabolic Syndrome and Lower Urinary Tract Symptoms: Hallym Aging Study.Canonical transient receptor potential channels in diabetes.Diabetes-related alterations in the enteric nervous system and its microenvironment.The relationships between metabolic syndrome, erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasiaAssociation between benign prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese men.Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled studyDifferential expression of nerve injury-induced protein 1 (ninjurin 1) in in vivo and in vitro models for diabetic erectile dysfunction.Time-dependent changes of erectile function in diabetic rats: role of systemic endothelial dysfunctionIncreased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis.Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey.Treatment strategies for diabetic patients suffering from erectile dysfunction: an update.How to treat erectile dysfunction in men with diabetes: from pathophysiology to treatment.Models for erectile dysfunction and their importance to novel drug discovery.Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.Metabolic Syndrome and Lower Urinary Tract Symptoms: Epidemiological Study.Surgical outcomes and complications of Tube® (Promedon) malleable penile prostheses in diabetic versus non-diabetic patients with erectile dysfunction.Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.Hydroxyl fasudil, an inhibitor of Rho signaling, improves erectile function in diabetic rats: a role for neuronal ROCK.Central modulation of the NO/cGMP pathway affects the MPOA-induced intracavernous pressure response.Corpus cavernosum dysfunction in diabetic rats: effects of combined alpha-lipoic acid and gamma-linolenic acid treatment.Epidemiology and pathophysiology of male sexual dysfunction.Characterization and diabetes-induced impairment of nitric oxide synthase in rat choroid.NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide.A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats.
P2860
Q28249515-31CF7C44-1C44-4628-88D0-F9853BAAF66DQ28366547-8E029D7C-8824-4EAB-BA76-34F63A49FA18Q28581593-E1A6C289-B725-4687-AC64-D2D11AB841A1Q30244250-87019945-849F-473D-BE49-7557072AD102Q34249452-C2219CA2-59F4-432A-A3D5-1356DF69AB0DQ34315631-1E0A8BE8-AADD-4537-BCAB-485F4EC12DFEQ34469704-304E2CF5-D9F6-4E03-98FD-B2E96B3CB29FQ34498189-6367FA84-BD81-469F-A76B-974256911B6FQ34515584-82E3FF0D-2121-4DED-88BF-830EBED00786Q35000972-A2AD4559-DF96-45A1-8CCC-D3F81AAC5227Q35001011-41B4ACDF-CB7D-4481-80C6-60349ED67048Q35050926-C0FA39C0-EF6B-4A15-9E96-4A800C26EB5AQ35154128-84197B5A-EEBB-49CD-A002-3D745D42ED5FQ35476177-F6DC0278-12DE-46D4-9E29-651C59CDA6ABQ35566587-BF7D54F8-133B-4D98-AC7A-11A985583246Q35741898-42AF0F31-80F4-4910-B537-02DB3EA67A01Q35823776-FC3F743F-9C33-4E4B-B765-8BDF39FCEB74Q35838500-5AA4A05D-D995-4BD1-820B-8A2856CBB31AQ35988135-98842923-2D05-4787-954A-C9851AE7A3D2Q35994047-9F85B597-47DA-4A3A-BEB1-7C76E91857CFQ36080363-56F88CAF-637D-4EBA-8195-2785D06D6E52Q36170066-05C7C53E-501B-423A-95FF-3BAC9CD82113Q36284761-8E9803FB-4C12-4CEA-82B6-01C077A30507Q36758102-974890DF-29D8-42C7-AB5C-69A18AFC2061Q37075004-F5DECDFE-8B67-4B86-BF1E-3B00B53D7FFEQ37406479-BBB20AC8-0B07-45DE-9B72-5EAFD3AC7F47Q38224353-91AFAEDD-5436-4296-8904-3FD5305DC475Q38246404-BE097BBC-6137-4D40-B7DD-6D396136E57FQ38675045-5E26CE5F-8D34-46BE-991E-93673EAD3FD6Q38692706-CBF6FF54-7B43-43C7-B380-1F9D525E7D08Q40202608-42A0E5C5-63F0-4E87-BC1A-0AFD531B352BQ40430635-81B68AF6-8D15-466C-ADFB-5DECC95C4FA4Q41585040-7E466405-C743-495D-B11E-FA5D33E69B54Q41891859-958ED0A6-6CB9-4930-B47B-F087125FE235Q43638793-7A1C1831-A9CA-4EEA-A127-B4949D3507E3Q43826056-C4C31AF6-C35D-4025-B6B9-03D1C5DFBC4BQ43985606-B23CD71F-5290-4AF7-BA4B-14F7FA83F7AEQ44108818-E20E9045-A264-41EB-B626-B6E2ED6A6729Q44762871-D661D433-865A-453E-8E2C-39D1BAA41B3DQ44804356-BED63F61-AE7D-462C-9C31-C7CDAC0E2D9B
P2860
Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Selective nitrergic neurodegen ...... ic oxide-dependent phenomenon.
@en
Selective nitrergic neurodegen ...... ic oxide-dependent phenomenon.
@nl
type
label
Selective nitrergic neurodegen ...... ic oxide-dependent phenomenon.
@en
Selective nitrergic neurodegen ...... ic oxide-dependent phenomenon.
@nl
prefLabel
Selective nitrergic neurodegen ...... ic oxide-dependent phenomenon.
@en
Selective nitrergic neurodegen ...... ic oxide-dependent phenomenon.
@nl
P2093
P2860
P356
P1476
Selective nitrergic neurodegen ...... ic oxide-dependent phenomenon.
@en
P2093
P2860
P304
P356
10.1038/SJ.BJP.0702981
P407
P577
1999-12-01T00:00:00Z